|8-(6-甲氧基吡啶-3-基)-3-甲基-1-(4-(哌嗪-1-基)-3-(三氟甲基)苯基)-1,3-二氢-2H-咪唑并[4,5-c]喹啉-2-酮马来酸盐|CsnPharm

CAS No.: 1245537-68-1

BGT226 maleate Catalog No. CSN15893

Synonyms: NVP-BGT226 maleate;BGT226;NVP-BGT226

NVP-BGT226 is a class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述The phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway is one of the most frequently dysregulated signaling cascades in human malignancies, it displays oncogenic potential and it is implicated in a wide variety of different neoplasms. NVP-BGT226 (BGT226), an imidazoquinoline derivative, an ATP-competitive dual PI3K/mTORC1/C2 inhibitor: it is a potent pan-class I PI3K inhibitor (p110α, β, δ, and γ, with a preference for the α-isoform -wild type and mutated-) and is a mTORC1/2 catalytic inhibitor. The IC50s of NVP-BGT226 is 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ^[3]. Because the pathway may not be completely inhibited after blockade of PI3K itself, due to feedback through mammalian target of rapamycin (mTOR), more effective inhibition might be expected by targeting both PI3K and mTOR inhibition. There is extensive crosstalk between the two signalling networks. mTOR can affect PI3K/Akt signalling through the S6K-IRS1 feedback loop and induce Akt phosphorylation by mTORC2. NVP-BGT226 can effectively block downstream targets and result in radiation sensitization in tumor cell lines and in endothelial cells^[4]. BGT226 could affect the viability of HCC cell lines, Mahlavu, SNU475, SNU449, HepG2 and Hep3B cells when they were incubated in the presence of increasing concentrations of the drug from 0.50 μM to 1.5 μM for either 24 or 48h. The experiments documented that already at 24h all the cell lines were very sensitive to BGT226. After 48h of treatment cell viability impairment was more evident, with an IC50 value ranging from 0.55 μM for Mahlavu to 1.35 μM for HepG2 cell^[5]. Oral administration of BGT226 at 2.5 and 5 mg/kg for 3 weeks caused 34.7% and 76.1% reduction of the tumor growth in the human FaDu xenografted mice on day 21, respectively (compared with control)^[6].
动物研究
剂量
BALB/c mice: 4 mg/kg, 8mg/kg^[3] (p.o.), 2.5 mg/kg - 5 mg/kg^[4] (p.o.)

给药途径
p.o.
参考文献

动物研究
剂量	BALB/c mice: 4 mg/kg, 8mg/kg^[3] (p.o.), 2.5 mg/kg - 5 mg/kg^[4] (p.o.)
给药途径	p.o.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.5370 mL
- 7.6852 mL
- 15.3703 mL
- 5 mM
- 0.3074 mL
- 1.5370 mL
- 3.0741 mL
- 10 mM
- 0.1537 mL
- 0.7685 mL
- 1.5370 mL

技术信息

CAS号

1245537-68-1

储存条件

粉末: Inert atmosphere,Store in freezer, under -20°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C32H29F3N6O6

运输

蓝冰

分子量

650.60

别名

NVP-BGT226 maleate;BGT226;NVP-BGT226

溶解度

DMSO	50.0 mg/mL (76.9 mM) warming
Water	5.0 mg/mL (7.7 mM) warming

动物实验配方

0.5% CMC-Na

62 mg/mL

suspension

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

BGT226 maleate Catalog No. CSN15893

靶点选择性

请登录您的专属账户

确认信息